Table 2.
Clinical characteristics of participants at time of testing for Covid-19, 1st March to 5th October 2020, Cameroon
| COVID-19 infection (PCR test) |
||||
|---|---|---|---|---|
| Characteristics | All participants N=85 206 | Positive (n=14 863) | Negative (n=70 343) | |
| Period of diagnosis | <0.001 | |||
| March | 1 338 (1.6) | 462 (3.1) | 876 (1.3) | |
| April | 7 765 (9.1) | 1 720 (11.6) | 6 045 (8.6) | |
| May | 19 225 (22.6) | 5 455 (36.7) | 13 770 (19.6) | |
| June | 15 296 (18.0) | 3 859 (26.0) | 11 437 (16.3) | |
| July | 7 754 (9.1) | 1 489 (10.0) | 6 265 (8.9) | |
| August | 14 226 (16.7) | 906 (6.1) | 13 320 (18.9) | |
| September | 19 602 (23.0) | 972 (6.5) | 18 630 (26.5) | |
| Age | 63 156* | 11 586 | 51 570 | |
| Median (IQR) - year | 36.5 (27.8-47.4) | 38.4 (29.6-49.4) | 36.1 (27.6-46.8) | <0.001 |
| Distribution – n/total (%) | ||||
| 0-18 | 5 580 (8.8) | 703 (6.1) | 4 877 (9.5) | |
| 19-29 | 13 763 (21.8) | 2 284 (19.7) | 11 479 (22.3) | |
| 30-49 | 30 934 (49.0) | 5 823 (50.3) | 25 111 (48.7) | |
| 50-64 | 10 025 (15.9) | 2 049 (17.7) | 7 976 (15.5) | |
| ≥65 | 2 854 (4.5) | 727 (6.3) | 2 127 (4.1) | |
| Gender | 84 796* | 14 804 | 69 992 | <0.001 |
| Female | 35 569 (42.0) | 6.262 (42.3) | 29 307 (41.9) | |
| Male | 49 227 (58.1) | 8 542 (57.7) | 40 685 (58.1) | |
| Coexisting disorders - n (%) | ||||
| Any | 3 464 (4.1) | 984 (6.6) | 2 480 (3.5) | <0.001 |
| Diabetes | 1 092 (1.3) | 369 (2.5) | 723 (1.0) | <0.001 |
| Chronic renal disease | 232 (0.3) | 70 (0.5) | 162 (0.2) | <0.001 |
| Cardiovascular | 1 632 (1.9) | 489 (3.3) | 1 143 (1.6) | <0.001 |
| Immunosuppression | 373 (0.4) | 91 (0.6) | 282 (0.4) | <0.001 |
| Asthma | 812 (1.0) | 184 (1.2) | 628 (0.9) | <0.001 |
| Drug history at sample collection - n (%) | ||||
| Antiviral | 775 (0.9) | 250 (1.7) | 525 (0.8) | <0.001 |
| Antibiotics | 5 465 (6.4) | 2 183 (14.7) | 3 282 (4.7) | <0.001 |
| Antimalarial | 5 655 (6.6) | 2 439 (16.4) | 3 216 (4.6) | <0.001 |
| Antipyretic | 6 996 (8.2) | 2 864 (19.3) | 4 132 (5.9) | <0.001 |
| Symptoms – n (%) | ||||
| No | 65 186 (76.5) | 7 953 (53.5) | 57 233 (81.4) | <0.001 |
| Any | 20 020 (23.5) | 6 910 (46.5) | 13 110 (18.6) | |
*The denominators of patients who were included in the analysis are provided if they differed from the overall numbers in the group